Evaluation of infections in non-small cell lung cancer patients treated with radiotherapy

被引:29
作者
Sarihan, S [1 ]
Ercan, I
Saran, A
Çetintas, SK
Akalin, H
Engin, K
机构
[1] Uludag Univ, Fac Med, Dept Radiat Oncol, TR-16059 Bursa, Turkey
[2] Uludag Univ, Fac Med, Dept Biostat, TR-16059 Bursa, Turkey
[3] AOS Oncol Hosp, Dept Radiat Oncol, Bursa, Turkey
[4] Uludag Univ, Fac Med, Dept Microbiol & Infect Dis, TR-16059 Bursa, Turkey
来源
CANCER DETECTION AND PREVENTION | 2005年 / 29卷 / 02期
关键词
non-small cell lung cancer; radiotherapy; infection; predisposing factors;
D O I
10.1016/j.cdp.2004.11.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: We aim to determine infections occuring in patients with non-small cell lung cancer during radiotherapy (RT). Methods and materials: A total of 181 patients had been treated with thoracic radiotherapy between October 1995 and December 1999. Radiotherapy was given using 1.8-3 Gray (Gy) fraction daily, five fractions a week for a total dose of 59.4 Gy (30-70.2 Gy). A complete history was collected retrospectively for each patient. All microbiological examinations were performed according to the routine procedures of the hospital laboratory. Numeric and categoric variables were employed such as sex, age, performance status, histology, stage, chemotherapy, usage of corticosteroids, neutropenia, surgery, hospitalization, associated diseases, smoking during treatment, package per year of cigarette smoking, dose of radiotherapy, and response rates. Results: Infections developed in 84 patients (46%, 84/181) during thoracic radiotherapy. A 101 episodes of infections developed in these patients. Most patients suffered from sputum production (65%), cough (59%), auscultation findings (31%) and fever (31%). Gram-negative bacteria were the most frequently isolated pathogens in the cultures of specimens (70%, 16/23 samples). Neoadjuvant chemotherapy (OR = 4.81; 95% CI, 1.57-9.12; p = 0.003) and neutropenia (OR = 4.25; 95% CI, 1.44-6.89; p = 0.009) were found as risk factors for influencing infection based on logistic regression analyses. Package per year of cigarette smoking was found statistically significantly higher in patients with infections than patients without infections (p = 0.001). A slight increase in infections, which was of borderline statistical significance (p = 0.07), was observed in patients age over 70. Ciprofloxacin and clarithromycin were the most frequently used agents in treatment. Median survival was 9 months in the patients with infection and 13 months in the 97 patients without infection. Overall survival seemed to be statistically significantly better in patients without infection than patients with infection (p = 0.042) calculated using Kaplan-Meier method. Based on Cox regression analyses; overall survival was not correlated to presence of infection but associated with poor performance status (<= 80) (OR = 2.35; 95% CI, 0.85-8.93; p = 0.03), and usage of corticosteroids (OR=2.68; 95% CI, 0.98-6.72; p = 0.01). The dose of radiation therapy > 5940 cGy (OR = 2.06; 95% CI, 0.72-7.18; p = 0.007) and the absence of response to treatment (OR = 2.45; 95% CI, 0.89-14.23; p < 0.001) were also found to be risk factors for survival. Conclusions: Infections are important causes of morbidity and mortality in lung cancer patients. The control of infection in these patients may improve the survival. Predisposing factors and treatment management approaches in non-small cell lung cancer should be defined carefully. (c) 2004 International Society for Preventive Oncology. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:181 / 188
页数:8
相关论文
共 50 条
  • [31] Prognostic factors in patients with brain metastasis from non-small cell lung cancer treated with whole-brain radiotherapy
    Harada, Hideyuki
    Asakura, Hirofumi
    Ogawa, Hirofumi
    Mori, Keita
    Takahashi, Toshiaki
    Nakasu, Yoko
    Nishimura, Tetsuo
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2016, 12 (01) : 267 - 270
  • [32] Dyspnea in Patients Receiving Radical Radiotherapy for Non-Small Cell Lung Cancer: A Prospective Study
    Sardaro, Angela
    McDonald, Fiona
    Bardoscia, Lilia
    Lavrenkov, Konstantin
    Singh, Shalini
    Ashley, Sue
    Traish, Daphne
    Ferrari, Cristina
    Meattini, Icro
    Asabella, Artor Niccoli
    Brada, Michael
    [J]. FRONTIERS IN ONCOLOGY, 2020, 10
  • [33] Radiotherapy for oligometastatic tumor improved the prognosis of patients with non-small cell lung cancer (NSCLC)
    Gong, Hong-yun
    Wang, Yi
    Han, Guang
    Song, Qi-bin
    [J]. THORACIC CANCER, 2019, 10 (05) : 1136 - 1140
  • [34] Cardiopulmonary morbidity and quality of life in non-small cell lung cancer patients treated with or without postoperative radiotherapy
    Kepka, Lucyna
    Bujko, Krzysztof
    Orlowski, Tadeusz M.
    Jagiello, Robert
    Salata, Andrzej
    Matecka-Nowak, Miroslawa
    Janowski, Henryk
    Rogowska, Danuta
    [J]. RADIOTHERAPY AND ONCOLOGY, 2011, 98 (02) : 238 - 243
  • [35] Effect of Increased Radiotoxicity on Survival of Patients with Non-small Cell Lung Cancer Treated with Curatively Intended Radiotherapy
    Holgersson, Georg
    Bergstrtom, Stefan
    Liv, Per
    Nilsson, Jonas
    Edlund, Per
    Blomberg, Carl
    Nyman, Jan
    Friesland, Signe
    Ekman, Simon
    Asklund, Thomas
    Henriksson, Roger
    Bergqvist, Michael
    [J]. ANTICANCER RESEARCH, 2015, 35 (10) : 5491 - 5497
  • [36] Prognostic implication of PD-L1 polymorphisms in non-small cell lung cancer treated with radiotherapy
    Kang, Min Kyu
    Lee, Shin Yup
    Choi, Jin Eun
    Do, Sook Kyung
    Cho, Moon-June
    Kim, Jun-Sang
    Park, Jae Yong
    [J]. CANCER MEDICINE, 2021, 10 (22): : 8071 - 8078
  • [37] Targeted therapy combined with thoracic radiotherapy for non-small cell lung cancer
    Yavas, Guler
    Yavas, Cagdas
    [J]. JOURNAL OF RADIATION ONCOLOGY, 2019, 8 (01) : 1 - 12
  • [38] A critical review of recent developments in radiotherapy for non-small cell lung cancer
    Sarah Baker
    Max Dahele
    Frank J. Lagerwaard
    Suresh Senan
    [J]. Radiation Oncology, 11
  • [39] Hyperfractionated radiotherapy for clinical stage II non-small cell lung cancer
    Jeremic, B
    Shibamoto, Y
    Acimovic, L
    Milisavljevic, S
    [J]. RADIOTHERAPY AND ONCOLOGY, 1999, 51 (02) : 141 - 145
  • [40] Combination of chemotherapy and radiotherapy for locally advanced non-small cell lung cancer
    Fournel, P.
    [J]. REVUE DES MALADIES RESPIRATOIRES, 2007, 24 (08) : S94 - S100